The global plasmid DNA contract manufacturing market size was estimated at USD 319.16 million in 2023 and is projected to hit around USD 1,879.54 million by 2033, growing at a CAGR of 19.4% during the forecast period from 2024 to 2033.
Key Takeaways:
The North America dominated the plasmid DNA contract manufacturing market in 2023 with a revenue share of 50.19%.
The Asia Pacific is anticipated to witness a lucrative growth rate of 19.9% across the analysis timeframe.
The cell & gene therapy segment held the leading market share at 62.3% in 2023 and is further anticipated to dominate the market during the forecast period.
The immunotherapy segment of the plasmid DNA contract manufacturing market is anticipated to witness a stable growth rate of 19.5% across the forecast period.
The pharmaceutical and biotechnology companies segment held the lion’s share of 61.2% in 2023.
The research institutes segment on the other hand is anticipated to witness a stable growth rate of 19.1% across the forecast period.
The cancer segment dominated the plasmid DNA contract manufacturing market with a revenue share of 41% in 2023.
The infectious diseases segment on the other hand is anticipated to witness a lucrative growth rate of 19.6% across the forecast period.
Market Overview
The Plasmid DNA (pDNA) Contract Manufacturing Market has evolved into a crucial pillar of the rapidly advancing gene and cell therapy, mRNA vaccine, and genetic immunotherapy industries. Plasmid DNA serves as a foundational component for a wide array of therapeutic modalities, including CAR-T cell therapies, DNA vaccines, CRISPR gene editing, and as starting material for mRNA manufacturing. The sharp increase in biopharmaceutical innovation and clinical activity in these areas has triggered an unprecedented demand for high-quality plasmid DNA, leading to a significant expansion in contract manufacturing capacity.
Plasmid DNA is particularly valued for its versatility, scalability, and non-viral nature. In the current post-pandemic era, where genetic medicine is gaining a stronger foothold, pDNA is no longer limited to academic research but is widely used in clinical and commercial pipelines. However, in-house plasmid manufacturing presents numerous challenges, such as complex regulatory compliance, high capital requirements, and process development constraints. Consequently, biotechnology and pharmaceutical companies are increasingly outsourcing this critical step to Contract Development and Manufacturing Organizations (CDMOs) that specialize in cGMP-grade plasmid DNA production.
The market has seen a surge in strategic investments, partnerships, and capacity expansion projects, especially in North America and Europe, where CDMOs are building specialized facilities to support clinical and commercial demand. Leading players such as Thermo Fisher Scientific, Catalent, VGXI, and Charles River Laboratories have positioned themselves as go-to partners for customized, end-to-end plasmid DNA manufacturing services. These CDMOs are also adopting automated platforms, single-use technologies, and high-density fermentation systems to improve yields and meet regulatory expectations.
Major Trends in the Market
Rapid Expansion of GMP-Compliant pDNA Facilities: CDMOs are investing heavily in infrastructure upgrades to meet regulatory standards for clinical and commercial-grade plasmid DNA.
Surge in Demand from mRNA and Gene Therapy Developers: Plasmid DNA serves as the DNA template for in vitro transcription (IVT) in mRNA production and is integral to viral vector manufacturing.
Adoption of High-Density Fermentation and Continuous Processing: New bioreactor technologies are being used to enhance plasmid yield and scalability while reducing costs.
Strategic Partnerships with Biopharma Companies: CDMOs are forming alliances with gene therapy developers to provide long-term manufacturing support.
Emergence of Modular and Single-Use Platforms: These technologies offer greater flexibility, faster turnaround times, and minimized contamination risk.
Increased Regulatory Scrutiny and Focus on Quality Systems: FDA and EMA are placing greater emphasis on documentation, traceability, and purity in plasmid manufacturing.
Integration of Analytics and AI for Process Optimization: CDMOs are using digital tools to streamline process development and ensure lot-to-lot consistency.
Geographic Expansion into Emerging Markets: Companies are setting up facilities in Asia-Pacific and Latin America to cater to regional demand and reduce shipping constraints.
Plasmid DNA Contract Manufacturing Market Report Scope
Report Attribute
Details
Market Size in 2024
USD 381.08 million
Market Size by 2033
USD 1,879.54 million
Growth Rate From 2024 to 2033
CAGR of 19.4%
Base Year
2023
Forecast Period
2024 to 2033
Segments Covered
Application, therapeutic area, end-user, region
Market Analysis (Terms Used)
Value (US$ Million/Billion) or (Volume/Units)
Report Coverage
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Key Companies Profiled
Charles River Laboratories, VGXI, Inc.; PlasmidFactory GmbH & Co. KG; Boehringer Ingelheim; BioCina; TriLink Biotechnologies; Aster PTE. LTD; Thermo Fisher Scientific, Inc.; VIVE biotech; Lonza
Market Driver: Booming Cell and Gene Therapy Pipelines
One of the most influential drivers for the plasmid DNA contract manufacturing market is the accelerating development of cell and gene therapies. These therapies, many of which are now in late-stage clinical trials or already approved, often require high-quality plasmid DNA as a raw material. For example, in CAR-T therapy, pDNA is used to create lentiviral vectors that deliver the therapeutic gene into T-cells. Similarly, in gene editing applications using CRISPR/Cas9, pDNA serves as the delivery mechanism for gene editing components.
The FDA has projected that by 2025, it will approve 10 to 20 cell and gene therapies each year, highlighting the clinical significance of this market. With over 2,000 active gene therapy clinical trials globally, CDMOs are witnessing increasing requests for phase-appropriate pDNA production. Contract manufacturers with GMP-compliant systems, viral vector expertise, and fill-finish capabilities are in high demand. Additionally, the scalability challenges faced by biopharma companies in-house make outsourcing not only a cost-effective solution but a strategic imperative.
Market Restraint: Production Complexity and Regulatory Barriers
Despite its growth potential, the plasmid DNA contract manufacturing market faces a major restraint in the complexity of large-scale GMP-compliant production. Unlike conventional biologics, pDNA requires bacterial fermentation, typically using E. coli, followed by purification processes that ensure the removal of impurities such as endotoxins, genomic DNA, and host cell proteins. Achieving high yields while maintaining supercoiled purity and compliance with regulatory specifications is technically demanding.
Moreover, regulatory agencies like the FDA and EMA have stringent guidelines governing pDNA used in therapeutic applications. These regulations cover everything from plasmid design and sequencing to batch release testing and documentation. The infrastructure investment required to meet these standards is substantial, often involving controlled cleanroom environments, validated equipment, and specialized personnel. These barriers limit market entry for new players and can create bottlenecks in supply chains, particularly when multiple clients compete for CDMO capacity.
Market Opportunity: mRNA Vaccines and Therapeutics Expansion
The rise of mRNA-based therapeutics and vaccines presents a transformative opportunity for the plasmid DNA contract manufacturing market. Plasmid DNA is used as the DNA template in the in vitro transcription (IVT) process to manufacture mRNA. With COVID-19 mRNA vaccines setting the precedent, companies are now exploring mRNA applications for influenza, Zika, HIV, cancer immunotherapy, and rare genetic disorders. Every one of these candidates requires large quantities of GMP-grade pDNA.
As biopharmaceutical firms and startups race to develop next-generation mRNA platforms, CDMOs capable of producing DNA templates at clinical and commercial scale are in high demand. For example, Moderna and Pfizer-BioNTech have heavily invested in supply chain resilience by partnering with or acquiring pDNA suppliers. This creates a fertile landscape for CDMOs to diversify their portfolios, offer end-to-end mRNA manufacturing solutions, and capture value across the genetic therapeutics ecosystem.
Segments Insights:
By Application Insights
Cell and Gene Therapy dominated the application segment, accounting for the majority of contract manufacturing demand. The use of plasmid DNA as a raw material for viral vector production in gene therapy, or directly in non-viral gene therapies, has driven this growth. With the increase in IND filings and gene therapy approvals in the U.S., CDMOs are scaling up to meet the clinical and commercial needs of biopharma clients. Plasmids are needed not only in bulk but also under stringent quality control, which reinforces the reliance on specialized partners for supply continuity.
Immunotherapy is the fastest-growing application, especially with the emergence of DNA vaccines and tumor-specific immunotherapies. Plasmid-based vaccines, such as Inovio’s DNA vaccine candidates, use pDNA to encode antigens that stimulate an immune response. This modality has gained renewed attention post-COVID-19, with efforts underway to apply it in cancer, autoimmune disorders, and infectious diseases. CDMOs are increasingly being tapped to produce GMP plasmids for such trials, highlighting this segment's rapid ascent.
By End-user Insights
Pharmaceutical and biotechnology companies dominated the market, owing to their extensive therapeutic pipelines and commercialization plans. These entities often lack the internal infrastructure to support plasmid manufacturing, making them the primary clients of CDMOs. From startups running Phase I trials to multinational companies launching commercial gene therapies, the reliance on external plasmid suppliers has become a market-defining trend.
Research institutes are a growing end-user segment, particularly as academic and nonprofit centers conduct translational research and early-stage clinical trials in gene therapy and cancer vaccines. Grants from organizations like the NIH and Gates Foundation have enabled research centers to collaborate with CDMOs for GMP-grade pDNA supply. These partnerships often pave the way for later-stage commercial collaboration, underscoring the value of engaging research clients early.
By Therapeutic Area Insights
Cancer emerged as the leading therapeutic area, driven by the dominance of plasmid-based applications in CAR-T therapy, tumor-targeted DNA vaccines, and gene-modified immune cell therapies. The growing prevalence of cancer and expanding pipeline of immuno-oncology assets have led to surging demand for customized pDNA constructs that support personalized therapies. Many CDMOs now offer fast-track plasmid services for oncology clients to speed up early-phase development.
Infectious diseases represent the fastest-growing area, particularly with the global focus on pandemic preparedness and vaccine innovation. DNA vaccines, which rely on plasmid backbones, are being actively pursued for pathogens like influenza, HIV, and respiratory syncytial virus (RSV). Additionally, the development of global mRNA vaccine capacity has further increased demand for pDNA templates used in IVT reactions. CDMOs are now positioning themselves to support not just Western developers, but also governments and regional vaccine manufacturers.
By Regional Insights
North America dominates the plasmid DNA contract manufacturing market, led by the United States. The region is home to a high concentration of gene therapy developers, robust regulatory support, and a mature CDMO ecosystem. Leading players like Thermo Fisher Scientific, Charles River Laboratories, and VGXI operate major pDNA production facilities across the U.S., offering scalable, GMP-compliant services to biopharma clients. The FDA's emphasis on gene therapy innovation and accelerated review programs further supports regional growth.
In February 2024, Thermo Fisher announced a $200 million expansion of its plasmid DNA facility in North Carolina to meet increasing demand from gene therapy and mRNA developers reinforcing the region’s leadership.
Asia-Pacific is the fastest-growing region in the plasmid DNA contract manufacturing market. Countries like China, India, South Korea, and Singapore are investing in biotech infrastructure, talent development, and regulatory reform to attract global CDMO partnerships. Local players and multinational CDMOs are setting up new facilities to serve the regional demand for gene therapies, vaccines, and RNA therapeutics. For example, WuXi AppTec has expanded its genetic medicine CDMO services, including plasmid DNA production, to cater to Asia-based and global clients.
With favorable cost structures, expanding clinical trial activity, and government support, Asia-Pacific is set to become a key node in the global pDNA supply chain.
Some prominent players in the global plasmid DNA contract manufacturing market include:
Charles River Laboratories
VGXI, Inc.
PlasmidFactory GmbH & Co. KG
Boehringer Ingelheim
BioCina
TriLink Biotechnologies
Esco Aster PTE. LTD
Thermo Fisher Scientific, Inc.
VIVE biotech
Lonza
Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Plasmid DNA Contract Manufacturing market.
By Application
Cell & Gene Therapy
Immunotherapy
Others
By Therapeutic Area
Cancer
Infectious Diseases
Autoimmune Diseases
Cardiovascular Diseases
Others
By End-user
Pharmaceutical and Biotechnology Companies
Research Institutes
By Region
North America
Europe
Asia-Pacific
Latin America
Middle East & Africa (MEA)
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook